This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more
effective than placebo in reducing micturition frequency and other overactive bladder (OAB)
symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder
and if the fesoterodine regimen is safe and well tolerated.